Last reviewed by Dr. Dharmender Malik on 14 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.
Introduction
To illustrate how Lu-177 PSMA-617 fits into the metastatic castration-resistant prostate cancer treatment pathway in practice, this article describes three anonymised composite case sketches. These are not real patients — they are composites constructed for educational purposes from common clinical patterns documented in the published trial cohorts (VISION, TheraP, PSMAfore) and routine clinical experience. No patient identifying information appears. The cases are included only to illustrate workflow, decision points, and the kind of clinical reasoning that underpins individual treatment decisions. Real patient decisions are always individualised through multidisciplinary review.
Important disclaimer — composite nature of these cases
AI Overview · short answer
Lu-177 PSMA-617 (Pluvicto) is FDA and EMA approved for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The original 2022 approval covered the post-taxane and post-androgen-pathway-inhibitor (ARPI) setting based on the VISION trial[1]. The 2025 FDA label expansion covered the pre-chemotherapy setting after ARPI progression based on the PSMAfore trial[2]. After Lu-177 PSMA-617 progression, standard alternatives include cabazitaxel, Ra-223 for symptomatic bone-metastatic disease, PARP inhibitors for HRR-mutated disease, repeat Lu-177 cycles in selected patients, and investigational pathways (Tb-161, Ac-225) under research-protocol oversight[3]. This article illustrates these scenarios through three anonymised composite case sketches.
The three case sketches that follow are composite, anonymised, and educational. They are not real patients. They are constructed from common clinical patterns documented in:
- The VISION trial (Sartor et al., NEJM 2021) — 831 patients in the post-taxane and ARPI mCRPC setting.
- The TheraP trial (Hofman et al., Lancet 2021) — 200 patients in the post-docetaxel mCRPC setting.
- The PSMAfore trial (2024) — pre-chemotherapy mCRPC after ARPI progression.
- Published Indian cohort experience including Yadav et al. (AIIMS, Indian J Nucl Med 2020) and others.
- Routine multidisciplinary tumour board patterns at established radioligand-therapy centres internationally.
No real patient data appears in this article. No real names are used. The specific PSA values, imaging findings, response patterns, and timing are illustrative — they represent typical patterns rather than any specific individual's experience. Individual outcomes vary substantially. The cases are intended only to illustrate clinical reasoning frameworks; they do not constitute medical advice for any specific patient.
Composite Case 1 — VISION-setting (post-taxane and ARPI mCRPC)
Background pattern. A man in his late 60s with metastatic prostate cancer initially presenting as de novo metastatic hormone-sensitive disease 4 years earlier. Original disease: PSA 380 ng/mL at presentation, Gleason 9 (5+4) on transrectal biopsy, multiple bone metastases and pelvic nodal disease on Ga-68 PSMA PET-CT, no visceral metastases. Family history negative for prostate or breast/ovarian cancer; germline panel testing negative for HRR-pathway mutations.
Prior systemic therapy sequence.
- Year 1: ADT (leuprolide) + docetaxel 6 cycles → biochemical response (PSA nadir 0.3), good radiographic response.
- Year 2: PSA progression to 4 ng/mL; switched to ADT + abiraterone + prednisone → PSA nadir 0.8 over 4 months, stable disease for 18 months.
- Year 4: PSA progression to 28 ng/mL with new pelvic node uptake on restaging; biochemical castration-resistance confirmed (testosterone 12 ng/dL).
Decision point — multidisciplinary tumour board review. Discussion at multidisciplinary tumour board: established options included cabazitaxel chemotherapy, Lu-177 PSMA-617 (under VISION-setting eligibility post-taxane and ARPI), and second androgen-pathway inhibitor switch. Ga-68 PSMA PET-CT confirmed PSMA-positive disease across bone and nodal sites; FDG PET-CT showed no PSMA-discordant disease. Adequate marrow (Hb 11, platelets 180, neutrophils 3.2) and kidney function (eGFR 72 mL/min). Patient values: continued aggressive disease-modifying therapy preferred over chemotherapy if eligible. Decision: Lu-177 PSMA-617 6-cycle protocol.
Treatment course.
- Cycle 1 (week 0): 7.4 GBq Lu-177 PSMA-617 IV; standard pre-medication; post-administration Lu-177 SPECT/CT confirmed intended distribution; mild fatigue 2-3 days post-cycle; biochemistry stable inter-cycle.
- Cycle 2 (week 8): standard 7.4 GBq; PSA response noted (28 → 9 ng/mL at week 4 between cycles 2 and 3).
- Cycle 3-4: standard activity; continued biochemical response; mild grade 1 thrombocytopenia at cycle 4 not requiring delay.
- Cycle 5-6: standard activity; PSA nadir at 0.6 ng/mL at end of cycle 6; restaging Ga-68 PSMA PET-CT showed substantial reduction in PSMA-positive disease burden.
Outcome pattern. Sustained biochemical and imaging response through 14 months post-cycle 6. PSA progression noted at 18 months. Discussion at multidisciplinary tumour board re-engaged options: cabazitaxel, repeat Lu-177 cycles given documented response (selected for in this composite), or investigational pathways.
What this composite illustrates. A typical VISION-setting Lu-177 PSMA-617 protocol — eligibility established at multidisciplinary review with Ga-68 PSMA PET-CT confirmation, six standard 7.4 GBq cycles at 6-8 week intervals, biochemical and imaging response monitoring, manageable side-effect profile, and structured re-engagement at progression. The specific PSA trajectory, response timing, and durability vary substantially across patients[4].
Composite Case 2 — PSMAfore-setting (pre-chemotherapy mCRPC)
Background pattern. A man in his mid-70s with metastatic prostate cancer that initially presented as biochemical recurrence after radical prostatectomy 6 years prior, with Ga-68 PSMA PET-CT-detected oligometastatic disease 3 years ago. Original prostatectomy pathology: Gleason 4+3 = 7 (Grade Group 3), pT3a N0 M0. Family history negative; germline panel negative for HRR-pathway mutations.
Prior systemic therapy sequence.
- Year 3 post-prostatectomy: PSA 0.8 ng/mL; Ga-68 PSMA PET-CT showed two PSMA-positive nodes in pelvis and a single PSMA-positive bone lesion in iliac crest.
- SBRT to oligometastatic sites + ADT (leuprolide) → biochemical response, PSA nadir undetectable, no further progression for 18 months.
- Year 5: PSA progression to 6 ng/mL; ADT continued; restaging showed multiple new bone metastases and additional pelvic nodal disease.
- Year 5.5: ADT + apalutamide → PSA nadir 0.4, stable disease for 14 months.
- Year 6.5: PSA progression to 12 ng/mL while continuing apalutamide; biochemical castration-resistance confirmed (testosterone 8 ng/dL); restaging Ga-68 PSMA PET-CT showed disease progression at multiple bone and nodal sites.
Decision point. mCRPC progressing on second-generation ARPI; not yet received chemotherapy. The 2025 FDA label expansion for Lu-177 PSMA-617 covers exactly this setting (PSMA-positive mCRPC progressing on prior ARPI, before chemotherapy), per PSMAfore evidence. Multidisciplinary tumour board options: switch to second ARPI (limited expected benefit per published data), docetaxel chemotherapy, or Lu-177 PSMA-617. Patient values: avoidance of chemotherapy-related fatigue and alopecia, willingness to undergo radioligand therapy. Ga-68 PSMA PET-CT confirmed PSMA-positive disease; FDG PET-CT showed concordant disease (no PSMA-negative component). Adequate organ reserve. Decision: Lu-177 PSMA-617 6-cycle protocol.
Treatment course. Six standard 7.4 GBq cycles at 6-8 week intervals, similar protocol to Composite Case 1. Biochemical response with PSA nadir at 0.7 ng/mL by end of cycle 4; sustained through cycle 6. Restaging at 3 months post-cycle 6 showed substantial reduction in PSMA-positive disease burden.
Outcome pattern. Sustained response at 12 months follow-up. The PSMAfore-setting approach (Lu-177 PSMA-617 before chemotherapy) is consistent with the 2025 label expansion. Treatment-related fatigue and grade 1 cytopenia present but did not require activity modification.
What this composite illustrates. The post-2025 label-expansion pathway — Lu-177 PSMA-617 can now be appropriate before chemotherapy in PSMA-positive mCRPC progressing on prior ARPI, providing an alternative to first-line cytotoxic chemotherapy for selected patients. Eligibility still requires Ga-68 PSMA PET-CT confirmation, multidisciplinary review, and informed-consent discussion of all alternatives[2].
Composite Case 3 — Post-Lu-177 progression
Background pattern. A man in his early 70s with metastatic prostate cancer originally presenting as de novo metastatic hormone-sensitive disease 5 years prior. Prior treatment sequence comprehensive: ADT + docetaxel; subsequent ADT + abiraterone; subsequent Lu-177 PSMA-617 6-cycle course in the VISION-setting; sustained response for 13 months post-cycle 6. Now presenting with documented progression: PSA risen from nadir 1.2 to 22 ng/mL over 4 months, restaging showing multiple new bone metastases on conventional bone scan, Ga-68 PSMA PET-CT showing continued PSMA-positive disease at most sites with limited PSMA-negative new disease (one liver lesion FDG-avid but PSMA-negative). Germline testing previously negative for HRR-pathway mutations. Performance status ECOG 1.
Decision point — multidisciplinary tumour board review. Options reviewed:
- Cabazitaxel — FDA / EMA approved, post-docetaxel evidence (TROPIC, CARD); appropriate next-line cytotoxic option.
- Ra-223 — symptomatic bone-metastatic CRPC indication; this patient has bone-dominant pattern but limited symptomatic burden currently.
- Repeat Lu-177 PSMA-617 cycles — selected patient pathway based on documented prior response, continued PSMA expression, adequate residual reserve. Not yet FDA-labelled for retreatment but reasonable at multidisciplinary review.
- Investigational pathways — Tb-161 PSMA-617 (VIOLET trial, Sydney; trial access required) or Ac-225 PSMA-617 (research-protocol cohorts including Sathekge experience). Both investigational; both require IRB-approved trial participation or compassionate-use authorisation, with full Helsinki-framework informed consent.
- Best supportive care — palliative care integration ongoing throughout.
The patient and family engaged with each option's expected benefit, side-effect profile, time-commitment implications, and uncertainty. Multidisciplinary discussion identified the small PSMA-negative liver lesion as an important consideration — it indicated heterogeneous disease where pure PSMA-targeted therapy alone might be inadequate.
Decision sequence. The composite case proceeded with combined approach: cabazitaxel chemotherapy for 4 cycles to address the PSMA-negative component, with PSMA imaging follow-up. Discussion of subsequent options (Ra-223, repeat Lu-177 cycles, investigational pathways) deferred to post-cabazitaxel restaging. Genetic re-testing on circulating tumour DNA initiated to identify any emergent HRR pathway mutations that would open PARP inhibitor options.
What this composite illustrates. Post-Lu-177 progression is rarely a single-option decision. The structured framework — Ga-68 PSMA PET-CT plus FDG PET to characterise PSMA-discordant disease, biomarker re-testing, multidisciplinary review of established and investigational options, integrated supportive care, and explicit patient-values incorporation — is more important than the specific sequence chosen. Different patients with broadly similar clinical patterns may make different reasonable decisions based on individual values and circumstances[5].
What the three composites together illustrate
Looking across the three composite cases, several patterns emerge that apply across the Lu-177 PSMA-617 patient population[6]:
- Eligibility decisions are multidisciplinary, not single-physician. All three composites went through formal multidisciplinary tumour board review. The decisions involved nuclear medicine, medical oncology, urology, and supportive care input.
- Ga-68 PSMA PET-CT eligibility imaging is mandatory. Every composite includes confirmation of PSMA expression on imaging prior to Lu-177 PSMA-617 delivery. FDG PET-CT may add value where PSMA-discordant disease is suspected.
- The treatment-line setting determines the appropriate evidence base. Composite 1 illustrates the VISION-setting; Composite 2 illustrates the PSMAfore-setting; Composite 3 illustrates the post-progression setting. Each has different evidence anchors and different alternative options.
- Patient values are explicit in decision-making. The choice between Lu-177 PSMA-617 and alternatives (chemotherapy, Ra-223, ARPI switch) often depends on patient values about treatment burden, side-effect tolerance, and time commitment, not solely on efficacy data.
- Re-engagement at progression is structured. Each composite includes plans for what happens at progression — repeat tumour-board review, updated imaging, possible biomarker re-testing, multiple alternative pathway options.
- Supportive care is integrated throughout. Bone-pain management, fatigue support, psychological care, and goals-of-care alignment are part of comprehensive care across all three composites — not deferred to end-of-life only.
Eligibility pattern summary — across the three settings
The eligibility pattern across the three settings illustrated:
| Setting | Trial / approval basis | Prior therapy required | Key eligibility criteria |
|---|
| VISION-setting (Composite 1) | FDA 2022 approval; VISION trial | Prior taxane (docetaxel/cabazitaxel) + ARPI | PSMA-positive disease on Ga-68 PSMA PET-CT; adequate organ reserve; ECOG 0-2 |
| PSMAfore-setting (Composite 2) | FDA 2025 label expansion; PSMAfore trial | Prior ARPI (abiraterone/enzalutamide/apalutamide/darolutamide); no prior chemotherapy | PSMA-positive disease on Ga-68 PSMA PET-CT; adequate organ reserve; ECOG 0-2; informed consent to forgo chemotherapy as next option |
| Post-progression (Composite 3) | Investigational; selective practice including emerging retreatment evidence | Prior Lu-177 PSMA-617 with documented prior response | Continued PSMA expression; adequate residual marrow and kidney; multidisciplinary review of all alternatives |
How individual decisions are actually made at FMRI
For an actual patient considering Lu-177 PSMA-617 at FMRI Gurugram, the decision process follows a structured five-point framework (consistent across the three composites and across the broader Lu-177 PSMA-617 patient cohort)[7]:
- (1) Eligibility review. Ga-68 PSMA PET-CT for PSMA expression confirmation, FDG PET-CT in selected patients for PSMA-discordant disease characterisation, organ reserve assessment (kidney function, marrow counts, liver function), prior-treatment history, performance status. The eligibility decision is documented in writing.
- (2) Procedure planning. Target activity (typically 7.4 GBq per cycle, 6 cycles at 6-8 week intervals), pre-medication, post-administration imaging plan, inter-cycle monitoring schedule.
- (3) Informed consent. Explicit discussion of expected benefit based on trial data (VISION, TheraP, PSMAfore as relevant to setting), expected side effects (fatigue, mild cytopenia, possible salivary-gland and renal effects), alternatives (cabazitaxel, Ra-223, PARP inhibitor if HRR-mutated, ARPI switch where applicable), limits and uncertainties.
- (4) Continuing care handover. Structured discharge documentation, treatment-summary letter to referring oncologist, imaging copies, biochemistry summary, radiation-safety instructions appropriate to home country / state.
- (5) Re-engagement at progression. Pre-scheduled review framework — imaging at planned intervals, biochemistry monitoring, multidisciplinary review at any progression signal. Multiple potential next-line pathways pre-discussed.
This framework applies whether the patient is in the VISION-setting (Composite 1), the PSMAfore-setting (Composite 2), or the post-progression setting (Composite 3). The framework does not change — what changes is the specific evidence base, the specific alternatives, and the specific patient factors.
Common patient questions these composites raise
Patients and families who read composite case sketches often have questions about how typical their situation might be:
- "How long did each composite patient respond?" Response durations in published cohorts vary substantially. VISION trial median radiographic PFS was 8.7 months; median overall survival 15.3 months. Individual response can be substantially longer (some patients show response for 2+ years) or shorter. The composites illustrate typical patterns, not specific predictions for any individual.
- "How many cycles will I receive?" Standard protocol is 6 cycles. Some patients receive fewer due to toxicity or progression; selected patients receive retreatment cycles after initial response. Composite 1 illustrates a standard 6-cycle course; Composite 3 illustrates the retreatment consideration.
- "How will I feel during treatment?" Common: fatigue (typically mild-moderate, post-cycle days 1-7), mild nausea, mild cytopenia. Less common: salivary gland dryness, mild renal effects, transient hair thinning. Most patients tolerate the 6-cycle course well. Specific side-effect profile is part of informed-consent discussion.
- "What happens after the 6 cycles?" Restaging at 3 months post-cycle 6 — Ga-68 PSMA PET-CT, biochemistry, clinical assessment. Subsequent monitoring at 3-6 month intervals. Decision-points for next-line therapy at progression.
- "What if I'm not eligible for Lu-177 PSMA-617?" Multiple FDA / EMA approved alternatives exist: cabazitaxel, Ra-223, PARP inhibitor (per biomarker status), ARPI options, supportive care. The choice depends on disease pattern, prior treatment, organ reserve, and patient values. Multidisciplinary review identifies the appropriate alternative pathway.
Why anonymised composites rather than real-patient testimonials
Three deliberate decisions about how these cases are presented[8]:
- Composites, not real patients. Real-patient case reports — even with informed consent — risk identification of the individual through clinical detail. Composite cases constructed from common trial-cohort patterns illustrate the same clinical reasoning without identification risk.
- Educational only, not testimonials. Patient testimonials selectively emphasise positive outcomes and may misrepresent the underlying outcome distribution. Composite cases that illustrate typical patterns — including the realistic challenges (progression, decision-making complexity, integrated supportive care) — provide more honest education.
- Anchored to trial evidence rather than anecdote. The composite case patterns derive from VISION, TheraP, PSMAfore, and published Indian cohort data — not from any single patient's experience. This grounds the illustration in the actual outcome distribution from the trial cohorts.
This approach is consistent with current best practice in evidence-based patient education and aligns with the broader audit-governance framework that nuclearmedicinetherapy.in operates under: no PII, no real-patient testimonials, neutral clinical framing, explicit grounding in published evidence base.
The bottom line
- These three case sketches are anonymised composites — not real patients — constructed from common patterns documented in the VISION, TheraP, PSMAfore, and Indian cohort published evidence base[1][2].
- Composite Case 1 illustrates the VISION-setting (post-taxane and ARPI mCRPC); FDA approved 2022; standard 6-cycle protocol with multidisciplinary review[1].
- Composite Case 2 illustrates the PSMAfore-setting (pre-chemotherapy mCRPC after ARPI progression); FDA label expansion 2025; alternative to first-line chemotherapy for selected patients[2].
- Composite Case 3 illustrates the post-Lu-177 progression decision pathway — established alternatives (cabazitaxel, Ra-223, PARP inhibitor where eligible, repeat Lu-177 cycles) and investigational pathways (Tb-161, Ac-225)[3].
- Across all three composites, the structured framework is consistent: Ga-68 PSMA PET-CT eligibility, multidisciplinary review, informed-consent discussion of all alternatives, structured cycle delivery, re-engagement at progression[7].
- Individual outcomes vary substantially from these composite patterns; specific PSA trajectory, response duration, and side-effect experience differ between individuals.
- The composite-case approach (rather than real-patient testimonial) reflects audit-governance best practice — no PII, no selective emphasis, anchored to published evidence base[8].
Important
The three case sketches in this article are anonymised composites — not real patients — constructed for educational purposes from common clinical patterns documented in published trial cohorts. No patient identifying information appears. Individual outcomes vary substantially from these composite patterns. The article does not constitute medical advice for any specific patient. Real treatment decisions are individualised through multidisciplinary review and informed consent.
"The three composite case sketches illustrate the structured framework that underlies every individual Lu-177 PSMA-617 decision: multidisciplinary review, Ga-68 PSMA PET-CT eligibility, informed-consent discussion of all alternatives, structured cycle delivery, and re-engagement at progression. The framework is consistent; what varies is the specific evidence base, alternatives, and patient values."
Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI
Lu-177 PSMA-617 eligibility review · FMRI
At FMRI Gurugram, Lu-177 PSMA-617 eligibility review covers Ga-68 PSMA PET-CT (PSMA expression confirmation), FDG PET-CT where indicated for discordant-disease assessment, organ reserve evaluation, prior treatment history, performance status, and explicit informed-consent discussion of all alternatives appropriate to the patient's specific treatment-line setting.
Request eligibility review · WhatsApp +91 8800 988936
For patients & referring clinicians
Frequently asked questions
Q01
Are these cases real patients?
No. The three case sketches in this article are anonymised composites — not real patients. They are constructed for educational purposes from common clinical patterns documented in the VISION, TheraP, PSMAfore, and published Indian cohort evidence base. No patient identifying information appears anywhere in this article. Individual outcomes vary substantially from these composite patterns; the cases illustrate workflow and decision frameworks, not specific predictions for any individual patient [8].
Q02
What is the VISION-setting?
The VISION-setting refers to the original 2022 FDA approval of Lu-177 PSMA-617 (Pluvicto), based on the VISION trial (Sartor et al., NEJM 2021). It covers PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have received both prior taxane chemotherapy (docetaxel or cabazitaxel) AND prior androgen-pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide). Median radiographic PFS in VISION: 8.7 vs 3.4 months (HR 0.40); median overall survival 15.3 vs 11.3 months (HR 0.62) [1].
Q03
What is the PSMAfore-setting?
The PSMAfore-setting refers to the 2025 FDA label expansion of Lu-177 PSMA-617 to cover the pre-chemotherapy setting. It applies to PSMA-positive mCRPC patients progressing on prior ARPI therapy who have not yet received chemotherapy. The label expansion was based on the PSMAfore trial, which demonstrated radiographic PFS benefit versus ARPI switch in this setting. Patients meeting PSMAfore eligibility criteria can now receive Lu-177 PSMA-617 before chemotherapy as a guideline-supported alternative to first-line docetaxel [2].
Q04
What if Lu-177 PSMA-617 stops working?
Several options remain after Lu-177 PSMA-617 progression. Established FDA / EMA approved options include cabazitaxel chemotherapy, Ra-223 for symptomatic bone-metastatic disease, PARP inhibitors for HRR-mutated disease, abiraterone or enzalutamide if not previously used, and repeat Lu-177 PSMA-617 cycles in selected patients with documented prior response. Investigational pathways include Tb-161 PSMA-617 (VIOLET trial) and Ac-225 PSMA-617. For full coverage see our companion post-Lu-177 progression article [3].
Q05
How many Lu-177 PSMA-617 cycles will I receive?
Standard protocol per FDA label and EANM procedure guidelines is six cycles of 7.4 GBq (200 mCi) Lu-177 PSMA-617 at 6-8 week intervals, totalling approximately 9-12 months of active therapy. Some patients receive fewer cycles due to toxicity or progression; selected patients with documented response and adequate residual organ reserve may receive retreatment cycles after the initial six-cycle course. The specific cycle plan is established at multidisciplinary review and documented in informed consent [1][7].
Q06
What is the typical response duration?
VISION trial median radiographic progression-free survival was 8.7 months (vs 3.4 months in the control arm). Individual response duration varies substantially: some patients show response for 2+ years, others substantially less. Response duration depends on disease characteristics (disease burden, distribution, prior treatment exposure, PSMA expression intensity), patient factors (organ reserve, performance status), and biomarker status. The composite case sketches in this article illustrate typical patterns; they do not predict specific individual outcomes [1][4].
Q07
What are common side effects?
Common side effects of Lu-177 PSMA-617 include: fatigue (typically mild-moderate, peaking post-cycle days 1-7), mild nausea, mild cytopenia (anaemia, thrombocytopenia, lymphopenia — usually grade 1-2 not requiring dose modification). Less common: salivary gland dryness (xerostomia, less prominent than with Ac-225 alpha therapy), mild renal effects, transient hair thinning. Rare but recognised: severe cytopenia requiring delay, more pronounced xerostomia, renal injury. Most patients tolerate the six-cycle course well; the specific side-effect experience is part of pre-treatment informed-consent discussion [4].
Q08
How is eligibility for Lu-177 PSMA-617 confirmed?
Eligibility is anchored to Ga-68 PSMA PET-CT imaging confirming PSMA expression on the patient's disease (positive uptake at tumour sites above background, typically using the Krenning-equivalent visual scoring or quantitative SUVmax thresholds). FDG PET-CT may be added in selected patients to identify PSMA-discordant disease (lesions visible on FDG but not PSMA). Additional eligibility criteria include adequate organ reserve (kidney, marrow, liver), ECOG performance status 0-2, and absence of trial-or-label-specific exclusions. The decision is documented at multidisciplinary tumour board review [7].
Q09
What is PSMA-discordant disease?
PSMA-discordant disease refers to lesions visible on FDG PET-CT but not on Ga-68 PSMA PET-CT — indicating disease that may not express PSMA at sufficient levels for Lu-177 PSMA-617 targeting. The presence of significant PSMA-discordant disease may reduce the expected benefit of Lu-177 PSMA-617 (because that disease component will not respond to PSMA-targeted therapy) and may prompt consideration of alternative or combination approaches (such as Lu-177 PSMA-617 plus chemotherapy for the discordant component). Composite Case 3 in this article illustrates this consideration [5].
Q10
Should I get genetic testing before Lu-177 PSMA-617?
Yes — germline and somatic genetic testing for HRR-pathway genes (BRCA1, BRCA2, ATM, CHEK2, PALB2, HOXB13) is recommended for all metastatic prostate cancer patients per NCCN and AUA guidelines. Findings inform: (1) PARP inhibitor eligibility — a major alternative or subsequent-line option to Lu-177 PSMA-617 for HRR-mutated patients; (2) prognosis discussion; (3) family screening if a germline pathogenic variant is identified. Testing is typically combined with genetic counselling. Most centres recommend testing at metastatic diagnosis; re-testing on circulating tumour DNA at progression points can identify emergent mutations [6].
Q11
Why composite cases rather than real testimonials?
Three reasons. (1) Real-patient testimonials risk identification even with informed consent through specific clinical detail. Composite cases constructed from common trial-cohort patterns illustrate the same clinical reasoning without identification risk. (2) Patient testimonials selectively emphasise positive outcomes and may misrepresent the underlying outcome distribution. Composite cases that illustrate typical patterns including realistic challenges provide more honest education. (3) Anchoring to trial evidence rather than anecdote grounds the illustration in actual outcome distributions from published cohorts. This approach reflects current best practice in evidence-based patient education [8].
Q12
How do I arrange a Lu-177 PSMA-617 eligibility review at FMRI?
At FMRI Gurugram, Lu-177 PSMA-617 eligibility review covers Ga-68 PSMA PET-CT (PSMA expression confirmation), FDG PET-CT where indicated for discordant-disease assessment, organ reserve evaluation, prior treatment history, performance status, and explicit informed-consent discussion of all alternatives appropriate to the patient's specific treatment-line setting (VISION, PSMAfore, or post-progression). WhatsApp +91 8800 988936 to begin a confidential review.
Citations & references
All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the regulatory archive — open in a new tab to verify.
[1] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION).
N Engl J Med. 2021;385(12):1091-1103.
View source ↗[2] Saad F, de Bono J, Chi KN, et al. PSMAfore trial of Lu-177 PSMA-617 in pre-chemotherapy mCRPC.
Lancet Oncol. 2024.
View source ↗[3] NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. National Comprehensive Cancer Network.
View source ↗[4] Hofman MS, Emmett L, Sandhu S, et al. [
177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP).
Lancet. 2021;397(10276):797-804.
View source ↗[5] Hofman MS, Lawrentschuk N, Francis RJ, et al. PSMA PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA).
Lancet. 2020;395(10231):1208-1216.
View source ↗[6] Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
N Engl J Med. 2016;375(5):443-453.
View source ↗[7] Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with
177Lu-labelled PSMA-ligands.
Eur J Nucl Med Mol Imaging. 2019;46(12):2536-2544.
View source ↗[8] World Medical Association. WMA Declaration of Helsinki — Ethical principles for medical research involving human subjects.
View source ↗[9] U.S. Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer (March 2022); label expansion (2025).
View source ↗[10] European Medicines Agency. Pluvicto (lutetium 177Lu vipivotide tetraxetan) Summary of Product Characteristics.
View source ↗[11] Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone (PCWG3).
J Clin Oncol. 2016;34(12):1402-1418.
View source ↗[12] Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II — 2024 Update.
Eur Urol. 2024.
View source ↗[13] de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer (CARD).
N Engl J Med. 2019;381(26):2506-2518.
View source ↗[14] Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer (ALSYMPCA).
N Engl J Med. 2013;369(3):213-223.
View source ↗[15] de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound).
N Engl J Med. 2020;382(22):2091-2102.
View source ↗[16] Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and Safety of
177Lu-PSMA-617 Radioligand Therapy in mCRPC.
Indian J Nucl Med. 2020;35(3):220-228.
View source ↗[17] Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (ARASENS).
N Engl J Med. 2022;386(12):1132-1142.
View source ↗[18] Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (CHAARTED).
N Engl J Med. 2015;373(8):737-746.
View source ↗[19] Hofman MS, Iravani A, Nzenza T, Hicks RJ. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Urol Clin North Am. 2018;45(3):503-524.
View source ↗[20] Atomic Energy Regulatory Board (Government of India). Safety Code for Nuclear Medicine Facilities. AERB/RF-MED/SC-2 (Rev. 2).
View source ↗[21] Drug Controller General of India / CDSCO. Drugs and Cosmetics Act and Rules.
View source ↗[22] International Atomic Energy Agency (IAEA). Quality Management Audits in Nuclear Medicine Practices (QUANUM).
View source ↗[23] Heidegger I, Tsaur I, Borgmann H, et al. Hereditary cancer syndromes and prostate cancer.
Nat Rev Urol. 2017;14(3):169-179.
View source ↗[24] Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA / ASTRO Guideline (2022).
View source ↗[25] Lowrance W, Dreicer R, Jarrard DF, et al. Updates to Advanced Prostate Cancer: AUA / SUO Guideline (2023).
View source ↗[26] Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology, 2024.
View source ↗[27] NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. National Comprehensive Cancer Network.
View source ↗[28] Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer.
N Engl J Med. 2010;363(8):733-742.
View source ↗[29] ESMO Clinical Practice Guidelines: Prostate Cancer. European Society for Medical Oncology.
View source ↗[30] Hofman MS, Buteau JP, Iravani A, et al. VIOLET phase 1/2 trial of
161Tb-PSMA-617. ClinicalTrials.gov NCT05521412.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.